DHE and POD® (Precision Olfactory Delivery) Technology | Trudhesa® (dihydroergotamine mesylate) nasal spray

Trudhesa unites DHE with gentle delivery

The medication in Trudhesa is called DHE or, dihydroergotamine mesylate. It has been used by specialists and hospitals for 70+ years. DHE is known for working when nothing else will.

When comparing Trudhesa to their regular migraine medication, more than half said that Trudhesa:

Worked faster

Lasted longer

Was more consistent

Got them back to normal activities quicker

84%

of people either agreed or strongly agreed Trudhesa was easy to use.^†

^†Results were from a poststudy questionnaire, which asked 354 people with migraine to rate their experience with Trudhesa against their best usual care. The results were patient-reported and not validated.

2/3

of people had pain relief after two hours.

In 4 previous studies of people using DHE with an older nasal spray device, many had no pain or mild pain at 2 hours.

Study 1

2 out of 3

people had pain relief

Study 2

50%

of people had pain relief

Studies 3 & 4

3 out of 10

of people had pain relief

There’s nasal.
And then there’s upper nasal

This area of the nose is rich in blood vessels, so medications can be quickly absorbed into your circulation.

It also means that the drug doesn’t need to take the journey through your gastrointestinal (GI) for it to work.

What relief at the ready could mean for you.

Speedy

Relief can start in as early
as 15 minutes*
Pain freedom at 2 hours – more than half of people were free from their most bothersome symptom at 2 hours*

Steady

With just 1 dose pain freedom was sustained for 2 days*
9 out of 10 people who were pain free at 2 hours were still pain free at 48 hours*
of all the migraine attacks treated, 85% didn’t require a second dose, and those who got relief with Trudhesa once, were likely to get relief again

At the Ready

Rates of pain freedom were the same whether people took Trudhesa within 2 hours or several hours into a migraine attack*

*Exploratory efficacy outcomes are based on patient reports and post hoc analyses from a phase 3, open-label safety study of Trudhesa.

^‡People with migraine were excluded if they had a history of CV events or presented with significant risk factors for CV disease. But people with a history of hypertension, if stable and well controlled on current therapies for >6 months, could enroll if no other risks were present.